News >

Immunotherapy Continues to Impress in GU Malignancies

Angelica Welch
Published: Tuesday, Nov 07, 2017

Andrea Apolo, MD

Andrea Apolo, MD
Single-agent immunotherapy continues to demonstrate durable responses in patients with urothelial carcinoma, and now, combination regimens are showing efficacy in both urothelial carcinoma and rarer genitourinary (GU) tumors.

 
In a phase I study, the combinations of cabozantinib (Cabometyx) plus nivolumab (Opdivo), as well as cabozantinib plus nivolumab and ipilimumab (Yervoy), are being investigated in patients with GU malignancies.1 Findings showed that, in the overall study population, the overall response rate (ORR) was 33%. Moreover, the ORRs with cabozantinib and nivolumab, and cabozantinib, nivolumab, and ipilimumab, were 38% and 22%, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x